Comparative efficacy and tolerability of sarilumab 150 and 200 mg in patients with active rheumatoid arthritis

Comparative efficacy and tolerability of sarilumab 150 and 200 mg in patients with active... Originalien 1 2 Z Rheumatol 2018 · 77:421–428 S.-C. Bae ·Y. H.Lee https://doi.org/10.1007/s00393-017-0292-6 Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Published online: 21 March 2017 Korea © Springer-Verlag Berlin Heidelberg 2017 Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea Redaktion U. Müller-Ladner, Bad Nauheim U. Lange, Bad Nauheim Comparative efficacy and tolerability of sarilumab 150 and 200 mg in patients with active rheumatoid arthritis A Bayesian network meta-analysis of randomized controlled trials Introduction Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovial joint inflammation, which leads to disability and loss of quality of life [6, 15]. Interleukin-6 (IL- 6) is a multifunctional cytokine involved in inflammatory responses and in the modulation of immune responses, in- cluding B cell and T cell differentiation [12]. IL-6 is overexpressed in the af- fected tissues of RA patients [21]and elevated levels of IL-6 in the serum andsynovial fluidare associated with synovitis, systemic inflammation, bone metabolism, and joint destruction [25]. A humanized, anti-human IL-6 receptor monoclonal antibody, tocilizumab, was designed to block IL-6 signaling and has been used as an effective therapeutic agent for http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Zeitschrift für Rheumatologie Springer Journals

Comparative efficacy and tolerability of sarilumab 150 and 200 mg in patients with active rheumatoid arthritis

Loading next page...
 
/lp/springer_journal/comparative-efficacy-and-tolerability-of-sarilumab-150-and-200-mg-in-bQiEBy6NBJ
Publisher
Springer Medizin
Copyright
Copyright © 2017 by Springer-Verlag Berlin Heidelberg
Subject
Medicine & Public Health; Internal Medicine; Rheumatology
ISSN
0340-1855
eISSN
1435-1250
D.O.I.
10.1007/s00393-017-0292-6
Publisher site
See Article on Publisher Site

Abstract

Originalien 1 2 Z Rheumatol 2018 · 77:421–428 S.-C. Bae ·Y. H.Lee https://doi.org/10.1007/s00393-017-0292-6 Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Published online: 21 March 2017 Korea © Springer-Verlag Berlin Heidelberg 2017 Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea Redaktion U. Müller-Ladner, Bad Nauheim U. Lange, Bad Nauheim Comparative efficacy and tolerability of sarilumab 150 and 200 mg in patients with active rheumatoid arthritis A Bayesian network meta-analysis of randomized controlled trials Introduction Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovial joint inflammation, which leads to disability and loss of quality of life [6, 15]. Interleukin-6 (IL- 6) is a multifunctional cytokine involved in inflammatory responses and in the modulation of immune responses, in- cluding B cell and T cell differentiation [12]. IL-6 is overexpressed in the af- fected tissues of RA patients [21]and elevated levels of IL-6 in the serum andsynovial fluidare associated with synovitis, systemic inflammation, bone metabolism, and joint destruction [25]. A humanized, anti-human IL-6 receptor monoclonal antibody, tocilizumab, was designed to block IL-6 signaling and has been used as an effective therapeutic agent for

Journal

Zeitschrift für RheumatologieSpringer Journals

Published: Mar 21, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off